ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

lebrikizumab

Also written as “Lebrikizumab”, “lebrikizumab (MILR1444A)” and “LY3650150”.

Its studies are mostly in Dermatitis, Atopic · Asthma · Nasal Polyps · Rhinitis, Allergic, Perennial · Pulmonary Disease, Chronic Obstructive, led by 4 companies.

Drug pageLebrikizumab: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since May 28, 202544 company-led studies, 7 open or runningNext primary completion: Apr 25, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Eli Lilly194 open or runningphase 4since May 28, 2025Feb 16, 2018May 2027phase 3 · NCT06338995
Hoffmann-La Rocheits history only180 open or runningphase 3since May 29, 2013Oct 27, 2008none ahead
Almirallits history only63 open or runningphase 3since Nov 26, 2021Nov 26, 2021Apr 25, 2027phase 3 · NCT06526182
Tanoxits history only10 open or runningphase 2since May 17, 2006May 17, 2006none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Eli Lilly only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Feb 16, 2018.

  1. Jan 30, 20202 phase 3 studies in Dermatitis, AtopicNCT04250350, NCT04250337
  2. May 13, 2020Phase 3 study in Dermatitis, AtopicNCT04392154 · 1,153 enrolled · United States, Australia, Bulgaria and more
  3. Nov 6, 2020Phase 3 study in Dermatitis, AtopicNCT04626297 · 254 enrolled · United States
  4. Feb 10, 2021Phase 3 study in Dermatitis, AtopicNCT04760314 · 286 enrolled · Japan
  5. Apr 9, 2021Phase 1 study in HealthyNCT04840901 · 242 enrolled · United States
  6. May 6, 20222 phase 3 studies in Dermatitis, AtopicNCT05369403, NCT05372419
  7. Sep 26, 2022Phase 3 study in Dermatitis, AtopicNCT05559359 · 377 enrolled · United States, Argentina, Australia and more
  8. Feb 10, 2023Phase 3 study in Dermatitis, AtopicNCT05735483 · 338 planned · United States, Argentina, Australia and more
  9. Jan 29, 2024Phase 1 study in HealthyNCT06243198 · 24 enrolled · China
  10. Feb 20, 2024Phase 3 study in Dermatitis, AtopicNCT06280716 · 301 enrolled · China, South Korea
  11. Mar 25, 20242 phase 3 studiesNCT06339008, NCT06338995
  12. Apr 4, 2025Phase 3 study in Atopic Hand and Foot DermatitisNCT06921759 · 221 enrolled · United States, Argentina, Australia and more
  13. May 28, 2025Phase 4 study in Dermatitis, AtopicNCT07006792 · 233 enrolled · United States, Argentina, Brazil and more
  14. Oct 27, 2026Primary completion moved from 2026-09 to 2026-10-22Date moved laterphase 3 · +1 months · NCT06339008

Ahead

  1. May 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)NCT06338995
  2. Dec 2027Primary completion: phase 3 study in Dermatitis, AtopicNCT05735483

TargetBeta

IL13 →read by rule
“A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities”NCIt, by rule
“Interleukin-13 inhibitor; Interleukin-13 inhibitor”ChEMBL 37, by rule

Other programs on IL13

ProgramCompanyFurthest phaseStudies
tilrekimigPfizerphase 311
lunsekimigSanofiphase 310
zumilokibartAbbViephase 24
ompekimigPfizerphase 23
GHZ339Novartisphase 21
ABBV-313AbbViephase 11

Studies

All 19 Eli Lilly leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07006792Dermatitis, Atopic · United States, Argentina, Brazil and more4CompletedMay 14, 2026233
NCT06921759Atopic Hand and Foot Dermatitis · United States, Argentina, Australia and more3CompletedMay 13, 2026221
NCT06339008Rhinitis, Allergic, Perennial · United States, Belgium, China and more3Active, not recruitingOct 22, 2026450
NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · United States, Argentina, Belgium and more3RecruitingMay 2027510
NCT06280716Dermatitis, Atopic · China, South Korea3CompletedSep 25, 2025301
NCT06243198Healthy · China1CompletedSep 3, 202424
NCT05735483Dermatitis, Atopic · United States, Argentina, Australia and more3By invitationDec 2027338
NCT05559359Dermatitis, Atopic · United States, Argentina, Australia and more3Active, not recruitingJan 14, 2026377
NCT05372419Dermatitis, Atopic · United States3CompletedMay 3, 202490
NCT05369403Dermatitis, Atopic · United States3CompletedJan 11, 202486
NCT04840901Healthy · United States1CompletedFeb 11, 2022242
NCT04760314Dermatitis, Atopic · Japan3CompletedJul 31, 2022286
NCT04626297Dermatitis, Atopic · United States3CompletedAug 3, 2022254
NCT04392154Dermatitis, Atopic · United States, Australia, Bulgaria and more3CompletedJul 19, 20241,153
NCT04250350Dermatitis, Atopic · United States, Australia, Canada and more3CompletedApr 20, 2022206
NCT04250337Dermatitis, Atopic · United States, Canada, Germany and more3CompletedAug 11, 2021228
NCT04178967Dermatitis, Atopic · United States, Bulgaria, Canada and more3CompletedJul 12, 2021445
NCT04146363Dermatitis, Atopic · United States, Australia, Canada and more3CompletedJun 21, 2021424
NCT03443024Dermatitis, Atopic · United States2CompletedFeb 7, 2019280

How it is read

Names in the registry

  • “Lebrikizumab”, 37 entries
  • “lebrikizumab”, 7 entries
  • “lebrikizumab (MILR1444A)”, 5 entries
  • “LY3650150”, 2 entries
  • “TNX-650”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.